File:Cyclophosphamide-2000-results.png: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
m (Text replacement - "|first3=" to " | first3 = ")
m (Text replacement - "|author-link6=" to " | authorlink6 = ")
Line 7: Line 7:
(C): mean steps per 24hrs;  
(C): mean steps per 24hrs;  
CI: confidence intervals.<br/>
CI: confidence intervals.<br/>
Numbers of patients at the different time points through follow-up are shown below the graphs.<ref name="Rekeland2020">{{Cite journal|last=Rekeland | first=Ingrid G.|author-link= | last2 = Fosså | first2 = Alexander|author-link2= | last3 = Lande | first3 = Asgeir|author-link3= | last4 = Ktoridou-Valen | first4 = Irini|author-link4= | last5 = Sørland | first5=Kari | authorlink5 =  | last6 = Holsen | first6 = Mari|author-link6=|last7 = Tronstad | first7=Karl J. | authorlink7 = Karl Tronstad|last8 = Risa | first8 = Kristin | authorlink8 = |last9 = Alme | first9 = Kine | authorlink9 = |date=2020|title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Frontiers in Medicine|language=English|volume=7|issue=162|pages=|doi=10.3389/fmed.2020.00162|issn=2296-858X|pmc=|pmid=|access-date=|quote=|via=|last10 = Viken | first10 = Marte K.|author-link10= | last11 = Lie | first11= Benedicte K.|author-link11= | last12 = Dahl | first12 =  Olav|author-link12= | last13 = Mella | first13 =  Olav|author-link13=Olav Mella | first14 =  Øystein | last14 = Fluge|author-link14=Øystein Fluge}}</ref>
Numbers of patients at the different time points through follow-up are shown below the graphs.<ref name="Rekeland2020">{{Cite journal|last=Rekeland | first=Ingrid G.|author-link= | last2 = Fosså | first2 = Alexander|author-link2= | last3 = Lande | first3 = Asgeir|author-link3= | last4 = Ktoridou-Valen | first4 = Irini|author-link4= | last5 = Sørland | first5=Kari | authorlink5 =  | last6 = Holsen | first6 = Mari | authorlink6 = |last7 = Tronstad | first7=Karl J. | authorlink7 = Karl Tronstad|last8 = Risa | first8 = Kristin | authorlink8 = |last9 = Alme | first9 = Kine | authorlink9 = |date=2020|title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Frontiers in Medicine|language=English|volume=7|issue=162|pages=|doi=10.3389/fmed.2020.00162|issn=2296-858X|pmc=|pmid=|access-date=|quote=|via=|last10 = Viken | first10 = Marte K.|author-link10= | last11 = Lie | first11= Benedicte K.|author-link11= | last12 = Dahl | first12 =  Olav|author-link12= | last13 = Mella | first13 =  Olav|author-link13=Olav Mella | first14 =  Øystein | last14 = Fluge|author-link14=Øystein Fluge}}</ref>
==== Author: (or citation) ====
==== Author: (or citation) ====
{{Cite journal|vauthors=Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø|date=2020|title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Front. Med.|language=English|volume=7|pages=162|doi=10.3389/fmed.2020.00162|pmc=|pmid=}}
{{Cite journal|vauthors=Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø|date=2020|title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Front. Med.|language=English|volume=7|pages=162|doi=10.3389/fmed.2020.00162|pmc=|pmid=}}

Revision as of 01:26, December 1, 2022

Summary[edit | edit source]

Title: (or description)[edit | edit source]

Cyclophosphamide ME/CFS trial results extended follow-up.
Key:
(A): SF-36 Physical Function (SF-36-PF); (B) percent function level; (C): mean steps per 24hrs; CI: confidence intervals.
Numbers of patients at the different time points through follow-up are shown below the graphs.[1]

Author: (or citation)[edit | edit source]

Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø (2020). "Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study". Front. Med. 7: 162. doi:10.3389/fmed.2020.00162.

Source: (e.g. internet address)[edit | edit source]

doi 10.3389/fmed.2020.00162 Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study

Other information:[edit | edit source]

See also[edit | edit source]

Licensing[edit | edit source]

Creative Commons
attribution
This file is licensed under the Creative Commons Attribution 4.0 International license.
You are free:
  • to share – to copy, distribute and transmit the work
  • to remix – to adapt the work
Under the following conditions:
  • attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

  1. Rekeland, Ingrid G.; Fosså, Alexander; Lande, Asgeir; Ktoridou-Valen, Irini; Sørland, Kari; Holsen, Mari; Tronstad, Karl J.; Risa, Kristin; Alme, Kine; Viken, Marte K.; Lie, Benedicte K.; Dahl, Olav; Mella, Olav; Fluge, Øystein (2020). "Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study". Frontiers in Medicine. 7 (162). doi:10.3389/fmed.2020.00162. ISSN 2296-858X.

File history

Click on a date/time to view the file as it appeared at that time.

Date/TimeThumbnailDimensionsUserComment
current21:28, January 26, 2022Thumbnail for version as of 21:28, January 26, 2022850 × 309 (67 KB)Notjusttired (talk | contribs)==== Title: (or description) ==== Cyclophosphamide ME/CFS trial results extended follow-up.<br> Key: <br> (A): SF-36 Physical Function (SF-36-PF); (B) percent function level; (C): mean steps per 24hrs; CI: confidence intervals.<br/> Numbers of patie...

There are no pages that use this file.